Restricted accessResearch articleFirst published online 2012-10
Inhibitory Metabolic Drug Interactions with Newer Psychotropic Drugs: Inclusion in Package Inserts and Influences of Concurrence in Drug Interaction Screening Software
Food and Drug Administration (FDA) regulations mandate that package inserts (Pls) include observed or predicted clinically significant drug-drug interactions (DDIs), as well as the results of pharmacokinetic studies that establish the absence of effect.
Objective:
To quantify how frequently observed metabolic inhibition DDIs affecting US-marketed psychotropics are present in FDA-approved Pls and what influence the source of DDI information has on agreement between 3 DDI screening programs.
Methods:
The scientific literature and Pls were reviewed to determine all drug pairs for which there was rigorous evidence of a metabolic inhibition interaction or noninteraction. The DDIs were tabulated noting the source of evidence and the strength of agreement over chance. Descriptive statistics were used to examine the influence of source of DDI information on agreement among 3 DDI screening tools. Logistic regression was used to assess the influence of drug class, indication, generic status, regulatory approval date, and magnitude of effect on agreement between the literature and PI as well as agreement among the DDI screening tools.
Results:
Thirty percent (13/44) of the metabolic inhibition DDIs affecting newer psychotropics were not mentioned in Pls. Drug class, indication, regulatory approval date, generic status, or magnitude of effect did not appear to be associated with more complete DDI information in Pls. DDIs found exclusively in Pls were 3.25 times more likely to be agreed upon by all 3 DDI screening tools than were those found exclusively in the literature. Generic status was inversely associated with agreement among the DDI screening tools (odds ratio 0.11; 95% CI 0.01 to 0.89).
Conclusions:
The presence in Pls of DDI information for newer psychotropics appears to have a strong influence on agreement among DDI screening tools. Users of DDI screening software should consult more than 1 source when considering interactions involving generic psychotropics.
Dal-RÉR, PedromingoA, Garci'a-LosaM, LahuertaJ, OrtegaR. Are results from pharmaceutical-company-sponsored studies available to the public?Eur J Clin Pharmacol2010; 66:1081–9. doi: 10.1007/s00228-010-0898-y
2.
HinesLE, Ceron-CabreraD, RomeroK. Evaluation of warfarin drug interaction listings in US product information for warfarin and interacting drugs. Clin Ther2011; 33:36–45.
3.
MarroumPJ, GobburaJ. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber. Clin Pharmacokinet2002; 41:161–9. doi: 10.1016/j.clinthera.2011.01.021
4.
SteinmetzKL, ColeyKC, PollockBG. Assessment of geriatric information on the drug label for commonly prescribed drugs in older people. J Am Geriatr Soc2005; 53:891–4. doi: 10.1111/j.1532–5415.2005.53273.x
5.
TulnerLR, FrankfortSV, GijsenGJPT. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging2008; 25:343–55. doi: 10.2165/00002512-200825040-00007
6.
GurwitzJH, FieldTS, JudgeJ. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med2005; 118:251–8. doi: 10.1016/j.amjmed.2004.09.018
7.
JuurlinkDN, MamdaniM, KoppA, LaupacisA, RedelmeierDA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA2003; 289:1652–8. doi: 10.1001/jama.289.13.1652
8.
HamiltonRA, BricelandLL, AndritzMH. Frequency of hospitalization after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy1998; 18:1112–20.
BoyceRD, HandlerSM, KarpJF, HanlonJT. Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information. Am J Geriatr Pharmacother2012; 10:139–50. doi: 10.1016/j.amjopharm.2012.01.001
11.
SpinaE, de LeonJ. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol2007; 100:4–22. doi: 10.1111/j.1742-7843.2007.00017.x
12.
SpinaE, AvenosoA, SalemiM. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry2000; 33:213–17. doi: 10.1055/s-2000-8361
13.
ChermáM, LöfgrenU, AlmkvistG, HallertC, BengtssonF. Assessment of the prescription of antidepressant drugs in elderly nursing home patients: a clinical and laboratory follow-up investigation. J Clin Psychopharmacol2008; 28:424–31. doi: 10.1097/JCP.0b013e31817d79eb
KarkareSU, BhattacharjeeS, KambleP, AparasuR. Prevalence and predictors of antidepressant prescribing in nursing home residents in the United States. Am J Geriatr Pharmacother2011; 9:109–19. doi: 10.1016/j.amjopharm.2011.03.001
HanstenPD, HornJR. The top 100 drug interactions, a guide to patient management. Freeland, WA: H & H Publications, LLP;2010.
20.
SpinaE, SantoroV, D'ArrigoC. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther2008; 30:1206–27. doi: 10.1016/S0149-2918(08)80047-1
21.
LandisJR, KochGG. The measurement of observer agreement for categorical data. Biometrics1977; 33:159–74. doi: 102307/2529310
22.
TurpeinenM, TolonenA, UusitaloJ. Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin Pharmacol Ther2005; 77:553–9. doi: 10.1016/j.clpt.2005.02.010
23.
FaridNA, PayneCD, ErnestSC2nd. Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol2008; 48:53–9. doi: 10.1177/0091270007309709
24.
MailingD, PoulsenMN, S⊘gaardB. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. Br J Clin Pharmacol2005; 60:287–90. doi: 10.1111/j.1365-2125.2005.02423.x
25.
LoboED, BergstromRF, ReddyS. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet2008; 47:191–202. doi: 10.2165/00003088-200847030-00005
26.
SkinnerMH, KuanH, PanA. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther2003; 73:170–7. doi: 10.1067/mcp.2003.28
27.
D'SouzaDL, DimmittDC, RobbinsDK. Effect of alosetron on the pharmacokinetics of fluoxetine. J Clin Pharmacol2001; 41:455–8. doi: 10.1177/00912700122010177
28.
GuptaS, BanfieldC, KantesariaB, FlanneryB, HerronJ. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. JClin Pharmacol2004; 44:1252–9. doi: 10.1177/0091270004269518
29.
SitsenJM, MarisFA, TimmerCJ. Concomitant use of mirtazapine and Cimetidine: a drug-drug interaction study in healthy male subjects. Eur J Clin Pharmacol2000; 56:389–94. doi: 10.1007/s002280000174
30.
SitsenJM, VoortmanG, TimmerCJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol2000; 14:172–6. doi: 10.1177/026988110001400207
31.
RuweFJL, SmuldersRA, KleijnHJ, HartmansHLA, SitsenJMA. Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Hum Psychopharmacol2001; 16:449–59. doi: 10.1002/hup.318
32.
DockensRC, GreeneDS, BarbhaiyaRH. Assessment of pharmacokinetic and pharmacodynamic drug interactions between nefazodone and digoxin in healthy male volunteers. J Clin Pharmacol1996; 36:160–7.
33.
GreeneDS, SalazarDE, DockensRC, KrobothP, BarbhaiyaRH. Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with tazepam. J Clin Psychopharmacol1995; 15:409–16. doi: 10.1097/00004714-199512000-00004
34.
Yasui-FurukoriN, SaitoM, InoueY. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol2007; 63:51–6. doi: 10.1007/S00228-006-0217-9
35.
AzzaroAJ, ZiemniakJ, KemperE, CampbellBJ, VanDenBergC. Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications. J Clin Pharmacol2007; 47:146–58. doi: 10.1177/0091270006296151
36.
LaineK, AnttilaM, HeinonenE. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol1997; 20:419–33. doi: 10.1097/00002826-199710000-00006
37.
KivistoKT, WangJS, BackmanJT. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol2001; 57:37–42. doi: 10.1007/s002280100278
38.
LaineK, AnttilaM, HelminenA, KarnaniH, HuupponenR. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Br J Clin Pharmacol1999; 47:249–54. doi: 10.1046/j.1365–2125.1999.00891.x
39.
NagyCF, KumarD, PerdomoCA. Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses. Br J Clin Pharmacol2004; 58(suppl 1):25–33. doi: 10.1111/j.1365-2125.2004.01801.x
40.
TroySM, RudolphR, MayersohnM, ChiangST. The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine. J Clin Pharmacol1998; 38:467–74.
41.
LindhJD, AnnasA, MeurlingL, DahlM, Al-ShurbajiA. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol2003; 59:401–6. doi: 10.1007/s00228-003-0627-x
42.
HynninenV, OlkkolaKT, BertilssonL. Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther2008; 83:342–8. doi: 10.1038/sj.clpt.6100311
43.
KuboM, KoueT, InabaA. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet2005; 20:55–64. doi: 10.2133/dmpk.20.55
44.
CitromeL, JosiassenR, BarkN, SalazarDE, MallikaarjunS. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol2005; 45:89–93. doi: 10.1177/0091270004269870
45.
GossenD, de SurayJ, VandenhendeF, OnkelinxC, GangjiD. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci2002; 4:E11. doi: 10.1208/ps040211
46.
WangC, ZhangZ, LiW. The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol2004; 44:785–92. doi: 10.1177/0091270004266621
47.
BerwaertsJ, CletonA, HerbenV. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. Pharmacopsychiatry2009; 42:158–63. doi: 10.1055/S-0029-1202265
48.
ThyssenA, CletonA, TalluriK. No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. Hum Psychopharmacol2009; 24:532–9. doi: 10.1002/hup.1049
49.
LiK, LiX, ChengZ. Effect of erythromycin on metabolism of quetiapine in Chinese suffering from schizophrenia. Eur J Clin Pharmacol2005; 60:791–5. doi: 10.1007/s00228-004-0853-x
50.
PotkinSG, ThyrumPT, AlvaG. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol2002; 22:121–30. doi: 10.1097/00004714-200204000-00004
51.
GrimmSW, RichtandNM, WinterHR, StamsKR, ReeleSB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol2006; 61:58–69. doi: 10.1111/j.1365–2125.2005.02507.x
52.
ReyesJF, PreskornSH, KhanA. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. Br J Clin Pharmacol2004; 58 (suppl 1):50–7. doi: 10.1111/j.1365-2125.2004.01817.x
53.
AmchinJ, ZarycranskiW, TaylorKP, AlbanoD, KlockowskiPM. Effect of venlafaxine on the pharmacokinetics of risperidone. J Clin Pharmacol1999; 39:297–309.
54.
WilnerKD, HansenRA, FolgerCJ, GeoffroyP. The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid. Br J Clin Pharmacol2000; 49 (suppl 1):57S–60S. doi: 10.1046/j.1365-2125.2000.00154.x
55.
MiceliJJ, SmithM, RobargeL, MorseT, LaurentA. The effects of ketoconazole on ziprasidone pharmacokinetics—a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol2000; 49 (suppl 1): 71S–6S. doi: 10.1046/j.1365-2125.2000.00156.x
56.
Sanchez GarciaP, CarcasA, ZapaterP. Absence of an interaction between ibuprofen and zaleplon. Am J Health Syst Pharm2000; 57:1137–41.
57.
GreenblattDJ, von MoltkeLL, HarmatzJS. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther1998; 64:661–71. doi: 10.1208/ps040211
58.
AllardS, SainatiS, Roth-SchechterB, MacIntyreJ. Minimal interaction between fluoxetine and multiple-dose Zolpidem in healthy women. Drug Metab Dispos1998; 26:617–22.
59.
PiergiesAA, SweetJ, JohnsonM, Roth-SchechterBF, AllardS. The effect of co-administration of Zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther1996; 34:178–83.
60.
HulhovenR, DesagerJP, HarvengtC. Lack of interaction between zolpidem and H2 antagonists, cimetidine and ranitidine. Int. J Clin Pharmacol Res1988; 8:471–76.
61.
LuurilaH, KivistöKT, NeuvonenPJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol1998; 54:163–6. doi: 10.1007/s002280050439
62.
SaariTI, LaineK, LeinoK. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol2007; 63:116–20. doi: 10.1111/j.1365-21252006.02707.x
63.
Product information.Celexa tablet/solution (Citalopram). St. Louis, MO: Forest Pharmaceuticals, February2009.
64.
Product information.Pristiq (desvenlafaxine) tablet, extended release for oral use. St. Louis, MO: Forest Pharmaceuticals, January2009.
65.
Product information.Cymbalta (duloxetine) capsule, delayed release. Indianapolis, IN: Eli Lilly and Company, January2010.
KustraR, CorriganB, DunnJ, DuncanB, HsyuPH. Lack of effect of Cimetidine on the pharmacokinetics of sustained-release bupropion. J Clin Pharmacol1999; 39:1184–8.
83.
KetterTA. Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol1995; 15:327–33. doi: 10.1097/00004714-199510000-00004
84.
LarsenF, PriskornM, Over⊘KF. Lack of Citalopram effect on oral digoxin pharmacokinetics. J Clin Pharmacol2001; 41:340–6. doi: 10.1177/00912700122010041
85.
GramLF, HansenMG, SindrupSH. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit1993; 15:18–24. doi: 10.1097/00007691-199302000-00003
86.
GutierrezM, AbramowitzW. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of Citalopram. Pharmacotherapy2001; 21: 163–8. doi: 10.1592/phco.21.2.163.34101
87.
BaumannP, NilR, SoucheA. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol1996; 16:307–14. doi: 10.1097/00004714-199608000-00006
88.
NoltingA, AbramowitzW. Lack of interaction between citalopram and the CYP3A4 substrate triazolam. Pharmacotherapy2000; 20:750–5. doi: 10.1592/phco.20.9.750.35198
89.
BarbhaiyaRH, ShuklaUA, GreeneDS, BreulHP, MidhaKK. Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol. J Clin Psychopharmacol1996; 16:26–34. doi: 10.1097/00004714-199602000-00005
90.
BarbhaiyaRH, ShuklaUA, GreeneDS. Lack of interaction between nefazodone and cimetidine: a steady state pharmacokinetic study in humans. Br J Clin Pharmacol1995; 40:161–5.
91.
KhanAY, PreskornSH, HorstWD. Coadministration of nefazodone and desipramine: a pharmacokinetic interaction study. J Pak Med Assoc2007; 57: 230–5.
92.
SalazarDE, MarathePH, FulmorIE, LeeJS, RaymondRH, UdermanHD. Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. J Clin Pharmacol1995; 35:1109–18.
93.
TroySM, ParkerVD, HicksDR, BoudinoFD, ChiangST. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium. J Clin Pharmacol1996; 36:175–81.
PotkinSG, ThyrumPT, AlvaG. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol2002; 22:174–82. doi: 10.1097/00004714-200204000-00011
KoY, MaloneDC, SkrepnekGH. Prescribers' knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf2008; 31:525–36. doi: 102165/00002018-200831060-00007
101.
ChaoSD, MaibachHI. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol2005; 6:105–11. doi: 10.2165/00128071-200506020-00005
102.
AnthonyM, RomeroK, MaloneDC. Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther2009; 86:425–9. doi: 10.1038/clpt.2009.95
103.
FuldaTR, ValuckRJ, ZandenJV. Disagreement among drug compendia on inclusion and ratings of drug-drug interactions. Curr Ther Res Clin Exp2000; 61:540–8. doi:16/S0011-393X(00)80036-3
104.
WangL, WongM, LightwoodJ, ChengC. Black box warning contraindicated comedications: concordance among three major drug interaction screening programs. Ann Pharmacother2010; 44:28–34. doi: 10.1345/aph.1M475
105.
AbarcaJ, MaloneDC, ArmstrongEP. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc2004; 44:136–41. doi: 10.1331/154434504773062582
106.
OlveyEL, ClauscheeS, MaloneDC. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther2010; 87:48–51. doi: 10.1038/clpt.2009.198
107.
WongC, KoY, ChanA. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother2008; 42:1737–48. doi: 10.1345/aph.1L255
108.
VitryAI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol2007; 63:709–14. doi: 10.1111/j.1365–2125.2006.02809.x
